Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) — CHRONOS-3

Lymphoma,Non-Hodgkin Clinical Trial

Official title:
A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-3

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have received one or more lines of treatment, including rituximab and who either had a treatment-free interval of ≥ 12 months after completion of the last rituximab-containing treatment, or who are unwilling to receive chemotherapy/for whom chemotherapy is contraindicated on reason of age, comorbidities, and/or residual toxicity.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02367040
Study type	Interventional
Source	Bayer
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	August 3, 2015
Completion date	August 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02996773` - Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine	Phase 1
Recruiting	`NCT02996617` - PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia	Phase 4
Not yet recruiting	`NCT03000738` - The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas	N/A